申请人:Merck Sharp & Dohme Limited
公开号:US05294618A1
公开(公告)日:1994-03-15
A class of 1,2,3,4,4a,5,6,10b-octahydrobenz[f]isoquinoline compounds and pharmaceutically acceptable salts of formula I: ##STR1## wherein, R.sup.1 represents hydrocarbon; R.sup.2 and R.sup.3 independently represent hydrogen, hydrocarbon, halogen, cyano, trifluoromethyl, nitro, --OR.sup.x, --SR.sup.x, --NR.sup.x R.sup.y, --CO.sub.2 R.sup.x or together represent methylenedioxy; and R.sup.x and R.sup.y independently represent hydrogen or hydrocarbon. The compounds disclosed herein are selective ligands at sigma recognition sites and are therefore useful in the treatment of psychiatric disorders.
一类1,2,3,4,4a,5,6,10b-八氢苯[f]异喹啉化合物和公认为药用的盐,其化学式为I:##STR1## 在此式中,R.sup.1代表碳氢化合物;R.sup.2和R.sup.3独立地代表氢、碳氢化合物、卤素、氰、三氟甲基、硝基、--OR.sup.x、--SR.sup.x、--NR.sup.x R.sup.y、--CO.sub.2 R.sup.x或一起代表亚甲二氧基;而R.sup.x和R.sup.y独立地代表氢或碳氢化合物。本文所披露的化合物是sigma识别位点的选择性配体,因此可用于治疗精神障碍。